



Anergis SA Announces the Appointment of Mr Jean-Paul Rohmer to the Company's Board of Directors

LAUSANNE, Switzerland – April 15, 2010 – Anergis SA, a clinical-stage biopharmaceutical company developing innovative specific immunotherapy against allergies, today announced the appointment of Mr Jean-Paul Rohmer to the Company's Board of Directors, as well as the re-election of Professor François Spertini and Mr Daniel Rey.

“Jean-Paul Rohmer is an outstanding senior pharmaceutical executive with a rare combination of skills and know-how which are of particular relevance to Anergis; Jean-Paul Rohmer brings extensive commercial experience from large pharma (Eli Lilly), in-depth understanding of allergen specific immunotherapy (Stallergenes) and extensive management experience from several biotech start-ups. His nomination to the Board of Directors brings critical value to Anergis and will help us in progressing efficiently with the development of our novel ultra-fast allergen specific immunotherapy products” commented Prof François Spertini, Founder and President of Anergis SA.

Mr Rohmer was elected to the Board of Directors of Anergis at the General Assembly of the Company held in Lausanne on April 12th, 2010. Professor François Spertini and Mr Daniel Rey were re-elected to the Board of Directors during the same meeting. Mr Rohmer also became a shareholder of Anergis SA on April 12th, 2010.

“We have worked very efficiently with Jean-Paul Rohmer as a regular consultant for a year now and we are today very pleased and honoured to welcome him inside the Company both as a Board member and as a shareholder” added Vincent Charlon, Chief Executive Officer of Anergis.

Jean Paul Rohmer, 63, is a French citizen who graduated with a Master in Economics and a Doctorate in Management Science from the University Paris IX Dauphine. His pharmaceutical career started in 1979 with Eli Lilly where he held various positions in market research, sales and marketing. In 1992, after several successful assignments with increasing responsibilities in different European countries, he was promoted Director of the Pharma Division of Eli Lilly France SA. In 1994, he joined Stallergenes (today the second largest company worldwide in allergen specific immunotherapy) as General Manager and then CEO. During that time, Stallergenes successfully went public in 1998 on the Paris Stock Market. Since 2000, Mr Rohmer is President and majority shareholder of a consultancy company (IDEFI-Gestion, Paris) providing assistance and support to new businesses in the biotech sector. In this quality, he was involved with a number of start-ups. Amongst other such missions, he was CEO of Meristem Therapeutics (Clermont-Ferrand), General Manager of the CEPH-Fondation Jean Dausset (Paris), CEO of Peptide Immune Ligands (Paris) and Board member and CEO of Biovector Therapeutics (Toulouse). Jean Paul Rohmer is currently Chairman of the Supervisory Board of the biotech company Medesis Pharma (Montpellier).

Anergis SA is a clinical-stage Swiss-based biopharmaceutical company specializing in the discovery and development of novel ultra-fast and safe specific immunotherapy products for the prevention and treatment of allergies. Allergy is the most prevalent and the fastest growing chronic condition in the industrialized world with over 300 million people affected. Current specific immunotherapy (“SIT”) remains underused due to its long duration (3-5 years of treatment) and safety risks. Anergis’ objective is to make SIT treatments available to an increasing number of allergic patients, by providing novel safe and ultra-fast immunotherapeutic products. Anergis possesses a unique know-how and the full rights to the technology of Contiguous Overlapping Peptides (“COPs”) developed jointly by the University of Lausanne, Switzerland (UNIL), the Federal Institute of Technology of Lausanne (EPFL) and the Centre Hospitalier Universitaire Vaudois (CHUV). The technology of COPs allows the identification and development of uniquely profiled proprietary products intended for ultra-fast and safe allergen specific immunotherapy. In the past years, Anergis has identified and studied proprietary



COPs targeting bee venom and tree pollen allergies, both in animals and in humans. These studies have clearly established the safety, tolerability and immunogenicity of the COP technology and the most recent study completed in 2009 with AllerT (against birch pollen allergies) showed an encouraging efficacy trend during the pollen season. Anergis is currently evaluating partnership options for its lead-product AllerT and for other COP products in development for common aero-allergies in various geographies.

Contacts:

Anergis SA
Vincent Charlon, CEO
Christophe Reymond, CSO

info@anergis.ch

www.anergis.ch